Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. immune functional
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Books
Downloads
Videos

Refine by
Date

  • This Year
  • Older

Immune Functional Articles & Analysis

28 news found

Alfa Chemistry Expands Portfolio with High-Purity Marine and Plant-Derived Bioactive Peptides

Alfa Chemistry Expands Portfolio with High-Purity Marine and Plant-Derived Bioactive Peptides

This expansion underscores Alfa Chemistry's commitment to supporting innovation in nutraceuticals, cosmeceuticals, functional foods, and biomedical research. Hydrolyzed peptides, derived from proteins broken down into smaller, more bioavailable chains of amino acids, are increasingly recognized for their targeted functional benefits - ranging from enhanced skin ...

ByAlfa Chemistry


BioZyme Launches VitaFerm Sure Start Gel

BioZyme Launches VitaFerm Sure Start Gel

VitaFerm Sure Start Gel supports newborn calves’ immune function and overall health during the critical post-birth period. ...

ByBioZyme Incorporated


Biotech Stock News Bite - Longeveron Inc. (NASDAQ: LGVN) Stock Soars on Clinical Pipeline and 2024 Key Priorities and Goals

Biotech Stock News Bite - Longeveron Inc. (NASDAQ: LGVN) Stock Soars on Clinical Pipeline and 2024 Key Priorities and Goals

We believe that by using the same cells that promote tissue repair, organ maintenance, and immune system function, we can develop safe and effective therapies for some of the most difficult diseases and conditions. ...

ByInvestorideas.com


Alfa Chemistry Integrates Its Supply of Dietary Supplement Ingredients   

Alfa Chemistry Integrates Its Supply of Dietary Supplement Ingredients  

Alfa Chemistry's dietary supplement ingredients supply encompasses a wide range of products, including functional ingredients, herbs and botanical extracts, health digestion aids, and food additives. ...

ByAlfa Chemistry


Creative Enzymes Introduces a Range of Lactobacillus Strains with Enhanced Benefits

Creative Enzymes Introduces a Range of Lactobacillus Strains with Enhanced Benefits

In recent years, extensive research has emphasized the critical role of gut health in maintaining a balanced immune system and overall vitality. Consequently, the demand for effective probiotic solutions has skyrocketed. ...

ByCreative Enzymes


Regor announces China NMPA approval of the IND for RGT-264 phosphate tablet, a potent and selective HPK1 inhibitor

Regor announces China NMPA approval of the IND for RGT-264 phosphate tablet, a potent and selective HPK1 inhibitor

HPK1 kinase activity suppresses the immune functions of a wide range of cells including T cells and dendritic cells (DCs) 1. ...

ByRegor Pharmaceuticals Inc.


Creative Proteomics Cytokine Boosts Your Research and Discovery with Mouse Cytokine Assay

Creative Proteomics Cytokine Boosts Your Research and Discovery with Mouse Cytokine Assay

Cytokines play an important role in physiological and pathological processes such as immune cell differentiation and subset development, immune regulation, inflammatory response, and tumor metastasis. ...

ByCreative Proteomics


Longeveron Enters into Cooperative Research and Development Agreement with the US Department of Veterans Affairs for its Phase 2 Alzheimer’s Trial

Longeveron Enters into Cooperative Research and Development Agreement with the US Department of Veterans Affairs for its Phase 2 Alzheimer’s Trial

The CLEAR MIND Trial, a Phase 2a study, is a blinded, randomized, placebo-controlled design investigating safety and tolerability, as well as secondary endpoints that include cognitive function and biomarkers, following single or multiple infusions of Lomecel-B compared to placebo, in individuals with mild AD. ...

ByLongeveron, Inc.


Longeveron Expands Executive Leadership Team; Appoints K. Chris Min, M.D., Ph.D. as Chief Medical Officer

Longeveron Expands Executive Leadership Team; Appoints K. Chris Min, M.D., Ph.D. as Chief Medical Officer

Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. ...

ByLongeveron, Inc.


Longeveron Publishes Peer Reviewed Study of Phase 1 Trial Results of Lomecel-B for Alzheimer’s Disease in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association

Longeveron Publishes Peer Reviewed Study of Phase 1 Trial Results of Lomecel-B for Alzheimer’s Disease in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association

Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. ...

ByLongeveron, Inc.


Prellis Biologics Announces Collaboration and License Agreement with Bristol Myers Squibb

Prellis Biologics Announces Collaboration and License Agreement with Bristol Myers Squibb

(Prellis), a Bay Area biotechnology company, announced today that it has entered into a multi-target drug discovery collaboration and licensing agreement with Bristol Myers Squibb utilizing Prellis Biologics’ first-in-class externalized human immune system (EXIS) based on human lymph node organoids (LNO). The collaboration leverages Prellis’ EXIS platform that can ...

ByPrellis Biologics, Inc.


Longeveron Announces Publication of Lomecel-B Phase 2b Trial Design in Journal of Frailty and Aging

Longeveron Announces Publication of Lomecel-B Phase 2b Trial Design in Journal of Frailty and Aging

Inflammation can contribute to the physical decline in Aging Frailty through multiple mechanisms, including detrimental effects on muscles, bone tissue, the immune system, cardiovascular function, and cognition. The necessity for identifying patients with Aging Frailty is well-acknowledged in the geriatric community, and the treatment of Aging Frailty and ...

ByLongeveron, Inc.


Longeveron Announces Initiation of Phase 2a Clinical Trial of Lomecel-B for the Treatment of Alzheimer’s Disease

Longeveron Announces Initiation of Phase 2a Clinical Trial of Lomecel-B for the Treatment of Alzheimer’s Disease

Dementia resulting from AD is associated with vascular function decline and involves a pro-inflammatory state. In Longeveron’s prior Phase 1 trial, Lomecel-B treatment met the primary safety endpoint, with no safety concerns – including no evidence of Alzheimer’s-related imaging abnormality, known as ARIA. ...

ByLongeveron, Inc.


Genmab and Synaffix Enter into $415m License Agreement for ADC Technology

Genmab and Synaffix Enter into $415m License Agreement for ADC Technology

Genmab’s proprietary pipeline includes bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. ...

BySynaffix BV


GI Innovation enters into clinical collaboration with AstraZeneca to explore Immuno-oncology GI-101 • Imfinzi® Combination Therapy

GI Innovation enters into clinical collaboration with AstraZeneca to explore Immuno-oncology GI-101 • Imfinzi® Combination Therapy

GI-101 contains an IL-2 domain, which can directly induce the activation and proliferation of cytotoxic T cells (CTL) and natural killer cells (NK) in the tumor microenvironment. GI-101 can further aid immune activation against tumor cells through its CD80 domain through CD80-CD28 interactions which leads to cytotoxic T cell activation and restraining CTLA-4, a ...

ByGI Innovation


Prellis Biologics Launches In Vitro Human Antibody Discovery Platform, Announces $14.5 Million Series B Investment, Key Executive Hires

Prellis Biologics Launches In Vitro Human Antibody Discovery Platform, Announces $14.5 Million Series B Investment, Key Executive Hires

“The EXIS platform offers unprecedented in vitro access to a functional human immune system. We’ve built a platform that enables promising science to be rapidly advanced into new patient therapies,” said Dr. ...

ByPrellis Biologics, Inc.


Prellis Biologics Launches In Vitro Human Antibody Discovery Platform, Announces $14.5 Million Series B Investment, Key Executive Hires

Prellis Biologics Launches In Vitro Human Antibody Discovery Platform, Announces $14.5 Million Series B Investment, Key Executive Hires

“The EXIS platform offers unprecedented in vitro access to a functional human immune system. We’ve built a platform that enables promising science to be rapidly advanced into new patient therapies,” said Dr. ...

ByPrellis Biologics, Inc.


Celularity Presents Preclinical Data on Allogeneic Genetically Modified Natural Killer (NK) and Allogeneic CAR-NK Cell Therapy Programs at the 63rd American Society of Hematology Meeting and Exposition

Celularity Presents Preclinical Data on Allogeneic Genetically Modified Natural Killer (NK) and Allogeneic CAR-NK Cell Therapy Programs at the 63rd American Society of Hematology Meeting and Exposition

In these studies, CYNK-101 was not susceptible to daratumumab-directed fratricide and did not display on-target, off-tumor cytotoxicity, suggesting CYNK-101 may be a unique NK cell platform that preserves innate immune function in the presence of daratumumab. Poster no. 2779: “Development of CD19 CAR Engineered Human Placental CD34+-Derived ...

ByCelularity Inc.


CytoReason and Summit Pharmaceuticals International Announce the Introduction of an AI Platform to One of Japan`s Top Pharmaceutical Companies

CytoReason and Summit Pharmaceuticals International Announce the Introduction of an AI Platform to One of Japan`s Top Pharmaceutical Companies

The company's technology enables scientists to gather critical information on the body's immune functioning, which ultimately speeds up the scientific process and brings life-saving drugs to market faster and at a reduced cost. ...

ByCytoReason


Data Driven: Immunai Adds Biocuration, European Hubs with Nebion Acquisition

Data Driven: Immunai Adds Biocuration, European Hubs with Nebion Acquisition

AMICA is a downloadable database of annotated multi-omic immune cells that includes information about gene expression, proteins, T-cell and B-cell receptors for immune cells, clinical and/or lab data, and a downloadable artificial intelligence software platform designed for characterizing and analyzing immune cells, as well as analyzing the ...

ByImmunai

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT